JMP Securities Initiates Coverage On AN2 Therapeutics with Market Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan has initiated coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform rating and set a price target of $30.

January 04, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AN2 Therapeutics received a Market Outperform rating from JMP Securities with a price target of $30, indicating a positive outlook from the analyst.
Analyst ratings, especially from reputable firms like JMP Securities, can significantly influence investor sentiment and stock prices in the short term. The Market Outperform rating suggests that the analyst believes ANTX will perform better than the broader market, and the $30 price target implies a substantial upside from current levels. This could lead to increased investor interest and a potential rise in ANTX's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100